Cell Therapy
Bayer’s BlueRock Lays Off 50 Employees, Shuts Cambridge Labs in Streamlining Move
BlueRock Therapeutics; Bayer; layoffs; biotech; Cambridge research labs; cell therapy; streamlining; bemdaneprocel; OpCT-001; pharmaceutical industry
Vertex’s Islet Cell Therapy Shows Dramatic Reduction in Dangerous Low Blood Sugar Levels in Type 1 Diabetes Trial
Vertex; islet cell therapy; zimislecel; Type 1 diabetes; hypoglycemia; phase 1/2 trial; endogenous insulin; stem cell therapy
FDA’s Top Cell and Gene Therapy Leaders Exit Amid CBER Upheaval
FDA; cell therapy; gene therapy; CBER; Nicole Verdun; Rachael Anatol; Peter Marks; leadership changes; biopharma regulation
BioNTech Halts Cell Therapy Manufacturing at Maryland Site, Lays Off Dozens
BioNTech; cell therapy; Maryland; layoffs; CAR-T; BNT211; Gaithersburg; manufacturing facility; cancer therapy; clinical trial
Illuminating the CKD Patient Journey: Clinicogenomic Data Reshapes Research & Drug Discovery
chronic kidney disease; CKD; clinicogenomics; drug discovery; cell therapy; gene therapy; clinical trials; personalized medicine
Forging the Future of Cell Therapy: Bayer and BlueRock’s Unique Journey
cell therapy; Bayer; BlueRock Therapeutics; Parkinson’s disease; bemdaneprocel; biotech partnerships; RMAT designation; Phase 3 trials; regenerative medicine
Galapagos Walks Back Split Plans, Raising Questions Over Cell Therapy Assets
Galapagos; company split; cell therapy; spinoff; CEO appointment; biotech industry; CAR T business
Galapagos Reconsiders Company Split After Market Developments
Galapagos; company split; cell therapy; drug development; strategic review; leadership change; market conditions
Biotech stocks plunge and industry figures left to wonder after Prasad’s FDA appointment
United States Food and Drug Administration, Industry, Prasad, Appointments, stocks, Cell Therapy, Market, figures
BMS to close Illinois site as part of cell therapy manufacturing consolidation
Bristol Myers Squibb, viral vector production, Libertyville Illinois, manufacturing consolidation, Novartis acquisition, cell therapy, cost cuts